NovaSignal appoints John Donovan to its Board as Independent Director

– USA, CA –  NovaSignal Corp., a medical technology and data company specializing in assessing cerebral blood flow, today announced the appointment of John M. Donovan to its Board as an independent director, effective August 26th.

Mr. Donovan most recently served as CEO of AT&T Communications.

“We are extremely fortunate to have John, a Fortune 100 leader and a visionary, join the NovaSignal board. John’s success in creating new businesses and influencing the industry is invaluable as we scale our business and establish NovaSignal as a global leader in technology-driven healthcare. I look forward to personally benefiting from John’s immense knowledge and experience,” said Chairman and CEO, Diane Bryant.

About John Donovan

A global technology leader and experienced board director, Mr. Donovan brings more than 30 years of experience in developing high-performing organizations, products, and markets. As CEO of AT&T Communications, he drove AT&T’s innovation and monetization of software-defined networking and network function virtualization, as well as spearheading AT&T’s push into 5G. Mr. Donovan joined AT&T in 2008 as CTO, overseeing the company’s global technology direction and innovation roadmap. He was promoted to Chief Strategy Officer and Group President, AT&T Technology and Operations, before being named CEO of AT&T Communications in July 2017. As CEO he was responsible for AT&T’s global telecommunications and video services businesses, including AT&T’s Business, Entertainment, and Technology & Operations groups.

Prior to joining AT&T, Mr. Donovan served as executive vice president of product, sales, marketing and operations at VeriSign Inc., an internet infrastructure company, chairman and CEO of inCode Telecom Group Inc., where he helped to shape strategy for wireless carriers worldwide, and a partner with Deloitte Consulting where he was the Americas industry practice director for telecom.

“I have tremendous respect for NovaSignal’s innovations in artificial intelligence, robotics, and cloud computing. The company vision of ending brain disease through cerebral blood flow analysis is inspiring and compelling,” said John Donovan. “I look forward to working with Diane, the other members of NovaSignal’s Board of Directors and the senior management team to capitalize on the many growth opportunities ahead.”

Mr. Donovan also serves on the Board of Directors for Palo Alto Networks [NYSE: PANW]. He has authored three books: The Value Enterprise (1998); Value Creating Growth (1999); and Building the Network of the Future: Getting Smarter, Faster, and More Flexible with a Software Centric Approach (2017). He received a B.S.E.E. from the University of Notre Dame and earned an M.B.A. in finance from the University of Minnesota.

About NovaSignal

Founded in 2013, NovaSignal Corp. is a medical technology company whose mission is to save lives by unlocking the hidden power of blood flow data. The company’s FDA-cleared Lucid Robotic System combines non-invasive ultrasound, robotics, and artificial intelligence to assess real-time cerebral blood flow. Using cloud computing and data analytics, NovaSignal supports physicians in their clinical decision making of diseases identified through cerebral blood flow. This includes strokes, intracardiac shunts, and intra-pulmonary shunts.

For more information: https://novasignal.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>